Brief: China Health Group Says Xien Tablet & Rivastigmine Hydrogen Tartrate API Approved For GMP Production
08/06/2020 24:42
June 8 (Reuters) - China Health Group Inc 8225.HK :
* XIEN TABLET & RIVASTIGMINE HYDROGEN TARTRATE API APPROVED
FOR
GMP PRODUCTION ON JUNE 5
* XIEN TABLET & RIVASTIGMINE HYDROGEN TARTRATE API GRANTED
DRUG
PRODUCTION APPROVAL BY NMPA
Source text https://bit.ly/2XEPEKU
Further company coverage: 8225.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Health
See all newsBrief: China Health Group Says Court Dismisses Application To Set Aside Arbitration Award
Brief: China Health Says China Medical Group Initiated Legal Proceedings
Brief: China Health Group Says Song Xuemei Tendered Resignation As Executive Director
Brief: China Health Group Says Revenue Recognized In 1Q22 & 2Q22 Has Been Partially Adjusted During 4Q22
Brief: China Health Group Makes Application To Stock Exchange For Resumption In Trading